fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Talzenna (talazoparib) + Xtandi (enzalutamide) prolongs overall survival in phase III TALAPRO-2 trial for prostate cancer

Written by | 16 Oct 2024

Pfizer Inc. announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna  (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor,… read more.

Positive CHMP opinion for Xtandi (enzaltamide) in additional recurrent early prostate cancer treatment setting – Astellas

Written by | 30 Mar 2024

Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Xtandi (enzalutamide)… read more.

CHMP positive for Talzenna + Xtandi (talazoparib + enzalutamide) to treatmetastatic castration-resistant prostate cancer – Pfizer

Written by | 17 Nov 2023

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Talzenna…. read more.

Xtandi accepted for EMA review for earlier type of prostate cancer – Astellas

Written by | 21 Sep 2023

Astellas announced that the European Medicines Agency (EMA) has validated its Type II variation for Xtandi (enzalutamide) for the treatment of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.